Primary Treatment Results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Wildeman, Maarten A ^a   Fles, Renske ^a   Herdini, Camelia ^b   Indrasari, Rai S ^b   Vincent, Andrew D ^a   Tjokronagoro, Maesadji ^b   Stoker, Sharon ^a   Kurnianda, Johan ^b   Karakullukcu, Baris ^a   Taroeno Hariadi, Kartika W ^b   Hamming Vrieze, Olga ^a   Middeldorp, Jaap M ^c   Hariwiyanto, Bambang ^b   Haryana, Sofia M ^b   Tan, I Bing ^a,b,d  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL; PLATINUM COMPLEX; TEMOPORFIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; INDONESIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PATIENT COUNSELING; PHOTODYNAMIC THERAPY; PRIMARY MEDICAL CARE; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INDONESIA; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PHOTOCHEMOTHERAPY; PROGNOSIS; RADIOTHERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877588041     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063706     Document Type: Article

References (44)

1. Sloan FA, Gelband H, editors (2007) Cancer control opportunities in low- and middle-income countries. Washington DC: Institute of Medicine of the National Academies.
2. Boyle P, Levin B (2008) World Cancer Report 2008; IARC Library Cataloguing in Publication Data.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
4. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, et al. (2010) Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 376: 1186-1193.
5. Kanavos P, (2006) The rising burden of cancer in the developing world. Ann Oncol 17Suppl 8: viii15-viii23.
6. Wildeman MA, Zandbergen J, Vincent A, Herdini C, Middeldorp JM, et al. (2011) Can an online clinical data management service help in improving data collection and data quality in a developing country setting? Trials 12: 190.
7. Gulley ML (2010) Molecular diagnosis of Epstein-Barr virus related diseases. the journal of molecular diagnosis.
8. Devi BC, Tang TS, Corbex M, (2007) Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak, Malaysia. Ann Oncol 18: 1172-1176.
9. Curado MP, Edwards B, Shin HR (2007) Cancer Incidence in Five Continents, Vol. IX. 2007. IARC Scientific Publications No. 160, Lyon, IARC.
10. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, et al. (2012) Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer.
11. Al Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, et al. (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16: 1310-1317.
12. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, et al. (2005) Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23: 6730-6738.
13. Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, et al. (2010) The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 10: 558.
14. Nyst HJ, Wildeman MA, Indrasari SR, Karakullukcu B, van Veen RL, et al. (2012) Temoporfin mediated photodynamic therapy in patients with local persistent and recurrent nasopharyngeal carcinoma after curative radiotherapy: A feasibility study. Photodiagnosis Photodyn Ther 9: 274-281.
15. Gondhowiardjo S, Prajogi G, Sekarutami S, (2008) History and growth of radiation oncology in Indonesia. Biomed Imaging Interv J 4: e42.
16. Slotman BJ, Cottier B, Bentzen SM, Heeren G, Lievens Y, et al. (2005) Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol 75: 349-354.
17. Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, et al. (2005) Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75: 355-365.
18. Levendag PC, Lagerwaard FJ, Noever I, dePan C, vanNimwegen A, et al. (2002) Role of endocavitary brachytherapy with or without chemotherapy in cancer of the nasopharynx. Int J Radiat Oncol Biol Phys 52: 755-768.
19. Akimoto T, Mitsuhashi N, Hayakawa K, Sakurai H, Murata O, et al. (1997) Split-course accelerated hyperfractionation radiotherapy for advanced head and neck cancer: influence of split time and overall treatment time on local control. Jpn J Clin Oncol 27: 240-243.
20. Lee N, Puri DR, Blanco AI, Chao KS, (2007) Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck 29: 387-400.
21. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, et al. (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61: 1107-1116.
22. Fles R, Wildeman MA, Sulistiono B, Haryana SM, Tan IB, (2010) Knowledge of general practitioners about nasopharyngeal cancer at the Puskesmas in Yogyakarta, Indonesia. BMC Med Educ 10: 81.
23. Prasad U, Pua KC, (2000) Nasopharyngeal carcinoma: a delay in diagnosis. Med J Malaysia 55: 230-235.
24. Alho OP, Teppo H, Mantyselka P, Kantola S, (2006) Head and neck cancer in primary care: presenting symptoms and the effect of delayed diagnosis of cancer cases. CMAJ 174: 779-784.
25. Koivunen P, Rantala N, Hyrynkangas K, Jokinen K, Alho OP, (2001) The impact of patient and professional diagnostic delays on survival in pharyngeal cancer. Cancer 92: 2885-2891.
26. Teppo H, Koivunen P, Hyrynkangas K, Alho OP, (2003) Diagnostic delays in laryngeal carcinoma: professional diagnostic delay is a strong independent predictor of survival. Head Neck 25: 389-394.
27. Cevenini R, Donati M, Caliceti U, Moroni A, Tamba I, et al. (1986) Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma. J Infect 12: 127-131.
28. Chen JY, Chen CJ, Liu MY, Cho SM, Hsu MM, et al. (1987) Antibodies to Epstein-Barr virus-specific DNase in patients with nasopharyngeal carcinoma and control groups. J Med Virol 23: 11-21.
29. Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, et al. (2007) Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 96: 623-630.
30. Tamada A, Makimoto K, Yamabe H, Imai J, Hinuma Y, et al. (1984) Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan. Cancer 53: 430-440.
31. de Vathaire F, Sancho-Garnier H, de The H, Pieddeloup C, Schwaab G, et al. (1988) Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. Int J Cancer 42: 176-181.
32. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, et al. (2004) Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 190: 53-62.
33. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, et al. (2006) Single-assay combination of Epstein-Barr Virus (EBV) E. J Clin Microbiol. 44: 1459-1467.
34. Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, et al. (2007) Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J Med Virol 79: 1710-1721.
35. Fachiroh J, Prasetyanti PR, Paramita DK, Prasetyawati AT, Anggrahini DW, et al. (2008) Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening. J Clin Microbiol 46: 1374-1380.
36. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM, (2009) Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma. Clin Vaccine Immunol 16: 706-711.
37. Ji MF, Yu YL, Cheng WM, Zong YS, Ng PS, et al. (2011) Detection of Stage I nasopharyngeal carcinoma by serologic screening and clinical examination. Chin J Cancer 30: 120-123.
38. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, et al. (2004) Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350: 2461-2470.
39. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Fachiroh J, et al. (2005) Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 43: 3066-3073.
40. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Paramita DK, et al. (2006) Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 119: 608-614.
41. Tune CE, Liavaag PG, Freeman JL, van den Brekel MW, Shpitzer T, et al. (1999) Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. J Natl Cancer Inst 91: 796-800.
42. Tong JH, Tsang RK, Lo KW, Woo JK, Kwong J, et al. (2002) Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res 8: 2612-2619.
43. Hutajulu SH, Indrasari SR, Indrawati LP, Harijadi A, Duin S, et al. (2011) Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. Mol Cancer 10: 48.
44. Wildeman MA, Fles R, Adham M, Mayangsari ID, Luirink I, et al. (2012) Short-term effect of different teaching methods on nasopharyngeal carcinoma for general practitioners in Jakarta, Indonesia. PLoS One 7: e32756.